Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bupivacaine-Induced Regeneration in Rabbit Extraocular Muscles: Implications for the Treatment of Strabismus.

Ophthalmology science·2026
Same author

Effects of Glial Cell Line-Derived Neurotrophic Factor and Ciliary Neurotrophic Factor on Extraocular and Limb Muscle Precursor Cells.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society·2026
Same author

Effects of fibroblast growth factor 2 on muscle precursor cells from mouse limb and extraocular muscle.

PloS one·2026
Same author

Intersurgeon Variability in Proptosis Reduction After Orbital Decompression for Thyroid Eye Disease: A Multicenter Analysis.

Ophthalmic plastic and reconstructive surgery·2025
Same author

Development of a Patient-Centered Outcome Tool for Blepharospasm: A Stepwise Modified Delphi Study.

Toxins·2025
Same author

Eyelid Position and Patient-Reported Aesthetic Outcomes Following Administration of Topical Oxymetazoline: A Prospective Cohort Investigation.

Journal of drugs in dermatology : JDD·2025

Related Experiment Video

Updated: Jun 14, 2026

Rat Model of Photochemically-Induced Posterior Ischemic Optic Neuropathy
14:54

Rat Model of Photochemically-Induced Posterior Ischemic Optic Neuropathy

Published on: November 29, 2015

Pegylated interferon alpha-associated optic neuropathy.

Kathleen T Berg1, Bruce Nelson, Andrew R Harrison

  • 1Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, USA.

Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
|March 31, 2010
PubMed
Summary
This summary is machine-generated.

Peginterferon alfa-2a therapy can cause nonarteritic anterior ischemic optic neuropathy (NAION), a vision-threatening condition. Patients experiencing vision loss during treatment should consider stopping interferon to potentially improve outcomes.

More Related Videos

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

Related Experiment Videos

Last Updated: Jun 14, 2026

Rat Model of Photochemically-Induced Posterior Ischemic Optic Neuropathy
14:54

Rat Model of Photochemically-Induced Posterior Ischemic Optic Neuropathy

Published on: November 29, 2015

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

Area of Science:

  • Ophthalmology
  • Neurology
  • Hepatology

Background:

  • Chronic hepatitis C infection is a significant global health concern.
  • Peginterferon alfa-2a is a common treatment for chronic hepatitis C.
  • Nonarteritic anterior ischemic optic neuropathy (NAION) is a leading cause of non-arteritic vision loss.

Observation:

  • A case of simultaneous bilateral NAION and peripheral neuropathy occurred in a patient treated with peginterferon alfa-2a for hepatitis C.
  • Symptoms emerged 19 weeks post-initiation of therapy.
  • While peripheral neuropathy and right eye vision improved after discontinuation, left eye vision worsened.

Findings:

  • A review identified 23 additional cases of NAION associated with interferon alfa therapy.
  • At least 12 of these patients experienced bilateral NAION.
  • Vision loss occurred between 1 and 40 weeks after starting therapy, with variable outcomes upon follow-up.

Implications:

  • Interferon alfa treatment carries a risk of inducing NAION.
  • Discontinuation of interferon therapy should be considered in patients developing NAION.
  • Careful risk-benefit assessment is crucial when managing hepatitis C patients on interferon therapy.